Precigen Inc (PGEN) - Total Liabilities
Based on the latest financial reports, Precigen Inc (PGEN) has total liabilities worth $126.72 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PGEN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Precigen Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Precigen Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Precigen Inc balance sheet assets.
Precigen Inc Competitors by Total Liabilities
The table below lists competitors of Precigen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kent Gida Maddeleri Sanayi ve Ticaret AS
IS:KENT
|
Turkey | TL408.76 Million |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
USA | $569.90 Million |
|
Enerflex Ltd.
NYSE:EFXT
|
USA | $1.58 Billion |
|
P/F Bakkafrost
F:6BF
|
Germany | €7.85 Billion |
|
Liberty Live Holdings, Inc. Series A Liberty Live Group Common Stock
NASDAQ:LLYVA
|
USA | $2.62 Billion |
|
Elmos Semiconductor SE
F:ELG
|
Germany | €308.86 Million |
|
Sociedad Punta del Cobre S.A
SN:PUCOBRE
|
Chile | CL$635.84 Million |
|
Boyd Group Services Inc.
NYSE:BGSI
|
USA | $2.14 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Precigen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PGEN net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precigen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precigen Inc (2011–2025)
The table below shows the annual total liabilities of Precigen Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $135.71 Million | +27.13% |
| 2024-12-31 | $106.75 Million | +228.02% |
| 2023-12-31 | $32.55 Million | -63.73% |
| 2022-12-31 | $89.72 Million | -64.47% |
| 2021-12-31 | $252.51 Million | +2.06% |
| 2020-12-31 | $247.41 Million | -35.58% |
| 2019-12-31 | $384.05 Million | +13.81% |
| 2018-12-31 | $337.45 Million | +12.37% |
| 2017-12-31 | $300.31 Million | -20.93% |
| 2016-12-31 | $379.82 Million | +37.04% |
| 2015-12-31 | $277.16 Million | +65.98% |
| 2014-12-31 | $166.98 Million | +89.48% |
| 2013-12-31 | $88.13 Million | -81.38% |
| 2012-12-31 | $473.20 Million | +40.80% |
| 2011-12-31 | $336.09 Million | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more